SCHEMBL1347474

SCHEMBL1347474

O=C(O)CCCC=CC[C@H]1C(=O)C[C@@H](O)[C@@H]1C=C[C@@H](O)CCC1Cc2ccccc2C1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGER3 P43115 4/20 0.69
PTGFR P43088 3/20 0.69
PTGER4 P35408 3/20 0.68
PTGER2 P43116 2/20 0.68
PTGIR P43119 2/20 0.68
PTGER1 P34995 2/20 0.68
NR1I2 O75469 1/20 0.68
ESR1 P03372 1/20 0.68
PGR P06401 1/20 0.68
HPGD P15428 1/20 0.68
TSHR P16473 1/20 0.68
TBXA2R P21731 1/20 0.68
MAPK1 P28482 1/20 0.68
OPRK1 P41145 1/20 0.68
PDE4D Q08499 1/20 0.68
MGLL Q99685 1/20 0.60
MEN1 O00255 1/20 0.54
THRB P10828 1/20 0.54
KMT2A Q03164 1/20 0.54
RAB9A P51151 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1347470 1.00 PTGER3 (0.69) PTGER3PTGFRPTGER4PTGER2PTGIR
SCHEMBL1347473 1.00 PTGER3 (0.69) PTGER3PTGFRPTGER4PTGER2PTGIR
SCHEMBL1348487 0.95 PTGFR (0.69) PTGER3PTGFRPTGER4PTGER2PTGIR
SCHEMBL1348485 0.95 PTGFR (0.69) PTGER3PTGFRPTGER4PTGER2PTGIR
SCHEMBL1348491 0.95 PTGFR (0.69) PTGER3PTGFRPTGER4PTGER2PTGIR
SCHEMBL23352763 0.86 MGLL (0.78) PTGER3PTGFRPTGER4PTGER2PTGIR
SCHEMBL3367843 0.86 MGLL (0.78) PTGER3PTGFRPTGER4PTGER2PTGIR
SCHEMBL13399725 0.86 MGLL (0.78) PTGER3PTGFRPTGER4PTGER2PTGIR
SCHEMBL3367848 0.86 MGLL (0.78) PTGER3PTGFRPTGER4PTGER2PTGIR
SCHEMBL3367851 0.86 MGLL (0.78) PTGER3PTGFRPTGER4PTGER2PTGIR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063240-B2 Prostaglandin E1 and E2 analogs for the treatment of various medical conditions CAYMAN CHEMICAL COMPANY, INCORPORATED (US) 2011-11-22 US disclosed
US-20090221654-A1 PROSTAGLANDIN E1 AND E2 ANALOGS FOR THE TREATMENT OF VARIOUS MEDICAL CONDITIONS CAYMAN CHEMICAL COMPANY (US) 2009-09-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090221654-A1 PROSTAGLANDIN E1 AND E2 ANALOGS FOR THE TREATMENT OF VARIOUS MEDICAL CONDITIONS PTGER1, PTGER4, PTGER2 PTGER3 5/4885PTGFR 10/4885PTGER4 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.